New blood test for diagnosing echinococcosis
Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis
This study is testing a new blood test to see if it can help doctors diagnose echinococcosis, a serious infection caused by tapeworms, more accurately and quickly.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 43 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 1 site (Besançon) |
| Trial ID | NCT05824442 on ClinicalTrials.gov |
What this trial studies
This study evaluates a new multiplex quantitative PCR technique aimed at improving the diagnosis of echinococcosis, a severe parasitic infection caused by tapeworms. The approach involves analyzing blood samples to enhance the sensitivity and accuracy of diagnosis compared to traditional methods. By confirming the presence of the parasite more effectively, the study seeks to facilitate timely and appropriate treatment for affected patients. The research is conducted at the Centre Hospitalier Universitaire de Besancon in France.
Who should consider this trial
Good fit: Ideal candidates include men and women over 18 years old who have been diagnosed with either alveolar or cystic echinococcosis.
Not a fit: Patients who are pregnant or those without health insurance may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could lead to earlier and more accurate diagnoses of echinococcosis, improving patient management and outcomes.
How similar studies have performed: While traditional serological techniques have shown good sensitivity, this multiplex qPCR approach is novel and has not been widely tested in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women aged \>18 years with a diagnosis of echinococcosis (Alveolar Echinococcosis or Cystic Echinococcosis) established according to the reference criteria * Signature of the informed consent form indicating that the subject has understood the purpose and the procedures required by the study and that he agrees to participate in the study and to comply with the requirements and restrictions about this study * Affiliation to a French social security scheme or beneficiary of such a scheme. Exclusion Criteria: * Legal incapacity or limited legal capacity * Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator * Subject without health insurance * Pregnant woman * Subject being in the period of exclusion from another study or provided by the "national volunteer file".
Where this trial is running
Besançon
- Millon — Besançon, France (Recruiting)
Study contacts
- Principal investigator: Delphine VERHOEVEN-WEIL, MD — CHU Besançon
- Study coordinator: Laurence MILLON, PharmD, PhD
- Email: lmillon@chu-besancon.fr
- Phone: 0370632353
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.